Collaborating Under ICH E6 (R3)
Explore how sponsors and CROs must rethink collaboration and embed quality into every layer of trial execution.
Explore how sponsors and CROs must rethink collaboration and embed quality into every layer of trial execution.
Explore how E6 (R3) reshapes trial design, oversight, and culture, and why the industry must be ready to respond.
ICH E6 (R3) sets a new global benchmark for Good Clinical Practice, modernizing oversight with principle-based, risk-driven, and digitally enabled trial design.
This blog explores how clinical research leaders are navigating post-Covid uncertainty, shifting buyer expectations, and the growing need for authenticity, trust, and AI-driven value.
The FDA’s latest guidance on dose optimization marks a pivotal shift in oncology drug development.
The FDA’s new guidance on marks a pivotal shift in clinical research, promoting accessibility while emphasizing the need for enhanced risk oversight.